...
首页> 外文期刊>Journal of vector borne diseases. >Insights following change in drug policy: A descriptive study for antimalarial prescription practices in children of public sector health facilities in Jharkhand state of India
【24h】

Insights following change in drug policy: A descriptive study for antimalarial prescription practices in children of public sector health facilities in Jharkhand state of India

机译:毒品政策变化后的见解:印度贾坎德邦公共部门卫生机构儿童抗疟疾处方实践的描述性研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background & objectives: Widespread resistance to chloroquine was the mainstay to implement artemisininbased combination therapy (ACT) in the year 2007 in few malaria endemic states in India including Jharkhand as the first line of treatment for uncomplicated Plasmodium falciparum malaria. This study was conducted in Jharkhand state of the country just after the implementation of ACT to assess the prevailing antimalarial drug prescribing practices, availability of antimalarial drugs and the acceptability of the new policy by the health professionals for the treatment of uncomplicated P. falciparum malaria patients particularly in children ≤15 yr of age. Methods: This is a cross-sectional study in children aged ≤15 yr with malaria or to whom antimalarial drug was prescribed. Main outcome measure was prescription of recommended ACT in children aged ≤15 yr with malaria in the selected areas of Jharkhand. Results: In the year 2008, artemisinin-based combination therapy (ACT) was implemented in 12 districts of the studied state; however, the availability of ACT was confirmed only in five districts. Antimalarial prescription was prevalent amongst the undiagnosed (8.4%), malaria negative (64.3%) and unknown blood test result (1.2%) suggesting the prevalence of irrational treatment practices. ACT prescription was very low with only 3.2% of confirmed falciparum malaria patients receiving it while others received either non-artesunate (NA) treatment (88.1%) including chloroquine (CQ) alone, CQ + Primaquine (PQ)/other drugs, sulphadoxine-pyrimethamine (SP) alone, SP + other drugs or artemisinin monotherapy (AM) treatment (6.3%). Still others were given nonantimalarial treatment (NM) in both malaria positive (0.3%) and malaria negative (2.1%) cases. Interpretation & conclusion: Despite the change in drug policy in the studied state the availability and implementation of ACT was a major concern. Nevertheless, the non-availability of blister packs for children aged ≤15 yr was the main hindrance in the implementation of the recommended antimalarial. Availability, training and participation of health professionals in decision-making are the key elements to improve adherence to new treatment guidelines. This study provided evidence for the requirement of age-specific blister packs in the country and the national programme has introduced age-specific blister packs in the country in 2010. This baseline information will be useful to monitor the progress in ACT implementation in the country.
机译:背景与目标:对氯喹的广泛耐药性是2007年在印度少数疟疾流行州实施以青蒿素为基础的联合疗法(ACT)的主要手段,其中包括贾坎德邦作为治疗非复杂性恶性疟原虫的第一线药物。这项研究是在实施ACT之后立即在该国的贾坎德邦州进行的,旨在评估现行的抗疟药处方做法,抗疟药的可获得性以及卫生专业人员对于治疗单纯性恶性疟原虫疟疾患者的新政策的接受程度尤其是≤15岁的儿童。方法:这是一项对年龄≤15岁的疟疾患儿或开了抗疟药的儿童的横断面研究。主要结局指标是在贾坎德邦某些地区患有疟疾的15岁以下儿童中推荐使用ACT处方。结果:2008年,在研究州的12个地区实施了基于青蒿素的联合治疗(ACT);但是,仅在五个地区确认了ACT的可用性。在未确诊(8.4%),疟疾阴性(64.3%)和未知血液检查结果(1.2%)中,普遍存在抗疟药处方,这表明普遍存在不合理的治疗方法。 ACT处方药的使用率非常低,只有3.2%的确诊的恶性疟疾患者接受了该药,而其他人则接受了非青蒿琥酯(NA)治疗(88.1%),包括单独的氯喹(CQ),CQ + Primaquine(PQ)/其他药物,磺胺多辛-单独使用乙胺嘧啶(SP),SP +其他药物或青蒿素单药(AM)治疗(6.3%)。在疟疾阳性(0.3%)和疟疾阴性(2.1%)的病例中,还有其他人接受了非抗疟治疗(NM)。解释与结论:尽管所研究国家的毒品政策发生了变化,但ACT的可用性和实施​​仍是一个主要问题。然而,对于≤15岁的儿童而言,无法获得泡罩包装是实施推荐的抗疟药的主要障碍。卫生专业人员的可用性,培训和参与是决策的关键要素,可提高对新治疗指南的依从性。这项研究为该国需要特定年龄的泡罩包装提供了证据,国家计划于2010年在该国引入了特定年龄的泡罩包装。该基准信息将有助于监测该国在实施ACT方面的进展。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号